Your browser doesn't support javascript.
loading
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Guardia, Cristina; Bianchini, Giampaolo; Arpí-LLucià, Oriol; Menendez, Silvia; Casadevall, David; Galbardi, Barbara; Dugo, Matteo; Servitja, Sonia; Montero, Juan Carlos; Soria-Jiménez, Luis; Sabbaghi, MohammadA; Peña, Raul; Madoz-Gúrpide, Juan; Lloveras, Belen; Lluch, Ana; Eroles, Pilar; Arribas, Joaquin; Pandiella, Atanasio; Gianni, Luca; Rojo, Federico; Rovira, Ana; Albanell, Joan.
Afiliação
  • Guardia C; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Bianchini G; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • Arpí-LLucià O; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Menendez S; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Casadevall D; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • Galbardi B; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Dugo M; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • Servitja S; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Montero JC; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • Soria-Jiménez L; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Sabbaghi M; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Peña R; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Madoz-Gúrpide J; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • Lloveras B; Centro de Investigación del Cáncer, IBSAL-CSIC-CIBERONC, Salamanca, Spain.
  • Lluch A; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Eroles P; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • Arribas J; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Pandiella A; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • Gianni L; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Rojo F; Department of Pathology, IIS-Fundación Jiménez Díaz-CIBERONC, Madrid, Spain.
  • Rovira A; Department of Pathology, Hospital del Mar, Barcelona, Spain.
  • Albanell J; INCLIVA Biomedical Research Institute, Hospital Clínico de Valencia-CIBERONC, Universitat de València, Barcelona, Spain.
Clin Cancer Res ; 27(18): 5096-5108, 2021 09 15.
Article em En | MEDLINE | ID: mdl-34385295
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Neuregulina-1 / Anticorpos Monoclonais Humanizados / Fibroblastos / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Neuregulina-1 / Anticorpos Monoclonais Humanizados / Fibroblastos / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha